West Reports Third-Quarter 2026 Results
WEST PHARMACEUTICAL SERVICES INC (WST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 West Reports Third-Quarter 2026 Results Raising Full-Year Net Sales and Adjusted-Diluted EPS guidance Exton, PA, October 29, 2026 – West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today
How this was made
The 30-second read
Why it matters
The raised guidance signals stronger demand for high‑value product components, potentially boosting the stock.
Market read
First‑report earnings and guidance raise for a S&P 500 constituent, likely to move the stock and influence the healthcare sector.
What to watch
Capital spending guidance was lowered, which could temper enthusiasm.
West Reports Third-Quarter 2026 Results Raising Full-Year Net Sales and Adjusted-Diluted EPS guidance
Third-quarter net sales increased 8.7%, organic net sales increased 11.9%, adjusted-diluted EPS increased 35.7%, reported operating profit margin expanded to 30.6%, and the company raised full-year net sales and adjusted-diluted EPS guidance.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net sales, three months ended September 30, 2026GAAP | $874.5M | – | 8.7% |
| Organic net sales, three months ended September 30, 2026non-GAAP | $866.7M | – | 11.9% |
| Gross profit, three months ended September 30, 2026GAAP | $347.4M | – | – |
| Gross profit margin, three months ended September 30, 2026GAAP | 39.7% | – | – |
| Research and development, three months ended September 30, 2026GAAP | $18.3M | – | – |
| Selling, general and administrative expenses, three months ended September 30, 2026GAAP | $112.9M | – | – |
| Other expense (income), net, three months ended September 30, 2026GAAP | −$51.2M | – | – |
| Operating profit, three months ended September 30, 2026GAAP | $267.4M | – | – |
| Reported operating profit margin, three months ended September 30, 2026GAAP | 30.6% | – | – |
| Adjusted operating profit, three months ended September 30, 2026non-GAAP | $221.5M | – | – |
| Adjusted operating profit margin, three months ended September 30, 2026non-GAAP | 25.3% | – | – |
| Income tax expense, three months ended September 30, 2026GAAP | $58M | – | – |
| Net income, three months ended September 30, 2026GAAP | $214M | – | – |
| Diluted EPS, three months ended September 30, 2026GAAP | $3.02 | – | 57.3% |
| Adjusted net income, three months ended September 30, 2026non-GAAP | $188.8M | – | – |
| Adjusted-diluted EPS, three months ended September 30, 2026non-GAAP | $2.66 | – | 35.7% |
| Net sales, nine months ended September 30, 2026GAAP | $2.59B | – | 14.2% |
| Organic net sales, nine months ended September 30, 2026non-GAAP | $2.54B | – | 13.2% |
| Gross profit, nine months ended September 30, 2026GAAP | $973M | – | – |
| Gross profit margin, nine months ended September 30, 2026GAAP | 37.5% | – | – |
| Operating profit, nine months ended September 30, 2026GAAP | $623.6M | – | – |
| Reported operating profit margin, nine months ended September 30, 2026GAAP | 24.1% | – | – |
| Adjusted operating profit, nine months ended September 30, 2026non-GAAP | $599.9M | – | – |
| Adjusted operating profit margin, nine months ended September 30, 2026non-GAAP | 23.1% | – | – |
| Net income, nine months ended September 30, 2026GAAP | $506.8M | – | – |
| Diluted EPS, nine months ended September 30, 2026GAAP | $7.09 | – | – |
| Adjusted net income, nine months ended September 30, 2026non-GAAP | $512.5M | – | – |
| Adjusted-diluted EPS, nine months ended September 30, 2026non-GAAP | $7.16 | – | – |
| Net cash provided by operating activities, nine months ended September 30, 2026GAAP | $403.4M | – | – |
| Capital expenditures, nine months ended September 30, 2026GAAP | −$125M | – | – |
| Shares purchased under share repurchase programs, nine months ended September 30, 2026GAAP | −$685.3M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Proprietary Products, three months ended September 30, 2026Organic net sales were $720.0 million, compared with $617.7 million, an increase of 16.6%. HVP Components net sales increased 19.7% and Standard Products net sales increased 2.9%. | $728.8M | – | 12.6% |
| West Vantage, three months ended September 30, 2026Organic net sales were $146.7 million, compared with $157.1 million, a decline of 6.6%. | $145.7M | – | (7.3)% |
| HVP Components, three months ended September 30, 2026Organic net sales were $469.1 million, compared with $390.0 million, an increase of 20.3%. HVP Components accounted for 53% of total company net sales in the quarter. | $466.7M | – | 19.7% |
| HVP Delivery Devices, three months ended September 30, 2026Organic net sales were $87.6 million, compared with $69.3 million, an increase of 26.4%, excluding foreign currency translation effects and the impact of the SmartDose® 3.5mL divestiture. | $99.1M | – | — % |
| Standard Products, three months ended September 30, 2026Organic net sales were $163.3 million, compared with $158.4 million, an increase of 3.1%. | $163M | – | 2.9% |
Full-Year 2026 outlook
- Revenue$3.41 billion to $3.42 billion
- NoteOrganic net sales growth: 11.3% to 11.6%
- NoteReported-diluted EPS (U.S. GAAP): $9.31 to $9.41
- NoteAdjusted-diluted EPS (Non-U.S. GAAP): $9.38 to $9.48
- NoteCapital spending: $215 million to $220 million
- NoteNo additional SmartDose® 3.5mL product sales are expected for the remainder of the year.
Capital returns
- The Company repurchased $231 million of stock in the quarter, bringing the year-to-date total to $685 million.
- Shares purchased under share repurchase programs were $(685.3) million for the nine months ended September 30, 2026, compared with $(134.0) million in the prior-year period.
- The Board of Directors declared a fourth-quarter dividend of $0.26 per share on October 19, 2026, an increase of 18% over the $0.22 per share paid in the prior quarter.
- Dividend payments were $(47.0) million for the nine months ended September 30, 2026, compared with $(45.4) million in the prior-year period.
What drove it
- Consolidated third-quarter organic net sales increased 11.9%.
- Proprietary Products organic net sales increased 16.6%, led by HVP Components organic net sales growth of 20.3%.
- HVP Delivery Devices organic net sales increased 26.4% after excluding foreign currency translation effects and the SmartDose® 3.5mL transaction.
- Reported operating profit margin was 30.6%, compared with 20.8%, while adjusted operating profit margin was 25.3%, compared with 21.1%.
- The company recorded a $55.7 million net gain on the sale of SmartDose® 3.5mL On-Body Delivery System assets during the three and nine months ended September 30, 2026.
Concerns
- West Vantage net sales decreased 7.3% and organic net sales declined 6.6% in the third quarter.
- Generics reported net sales decreased 5.7% and organic net sales declined 4.5% in the third quarter.
- Year-to-date operating cash flow was $403.4 million, compared with $503.7 million in the prior-year period.
- The company recorded a one-time tax cost of $22.4 million associated with the gain on the sale of SmartDose® 3.5mL On-Body Delivery System.
- No additional SmartDose® 3.5mL product sales are expected for the remainder of the year.
What to watch
- Execution against full-year net sales guidance of $3.41 billion to $3.42 billion and organic net sales growth guidance of 11.3% to 11.6%.
- Execution against full-year adjusted-diluted EPS guidance of $9.38 to $9.48 and reported-diluted EPS guidance of $9.31 to $9.41.
- Whether HVP Components sustains its 20.3% third-quarter organic growth rate.
- Whether West Vantage, which declined 6.6% organically in the third quarter, improves.
- Capital spending within updated guidance of $215 million to $220 million.
Balance sheet and cash flow
- Cash and cash equivalents were $464.1 million as of September 30, 2026, compared with $791.3 million as of December 31, 2025.
- Long-term debt was $202.9 million as of September 30, 2026, compared with $202.8 million as of December 31, 2025.
- Net cash provided by operating activities was $403.4 million for the nine months ended September 30, 2026, compared with $503.7 million in the prior-year period.
- Capital expenditures were $(125.0) million for the nine months ended September 30, 2026, compared with $(209.8) million in the prior-year period.
- Proceeds from sale of assets were $126.9 million and disbursement associated with the sale of assets was $(8.9) million for the nine months ended September 30, 2026.
- Net cash used in financing activities was $(715.3) million for the nine months ended September 30, 2026, compared with $(173.4) million in the prior-year period.
Analysis
West reported a strong third quarter, with net sales of $874.5 million, up 8.7%, and organic net sales of $866.7 million, up 11.9%. Proprietary Products was the principal growth engine, with sales of $728.8 million and organic growth of 16.6%. HVP Components delivered $466.7 million of sales, increased 19.7%, and represented 53% of company net sales. HVP Delivery Devices reported flat sales of $99.1 million, but organic sales increased 26.4% after the specified foreign-exchange and SmartDose® 3.5mL adjustments.
Profitability expanded materially. Gross profit margin was 39.7%, compared with 36.6%, while reported operating profit margin was 30.6%, compared with 20.8%. Adjusted operating profit rose to $221.5 million from $170.1 million and the adjusted operating profit margin was 25.3%, compared with 21.1%. GAAP diluted EPS was $3.02, up 57.3%, and adjusted-diluted EPS was $2.66, up 35.7%. Reported results included a $55.7 million gain on the sale of SmartDose® 3.5mL On-Body Delivery System assets, reflected within M&A activities in the non-GAAP reconciliation.
The performance was not uniform across the portfolio. West Vantage sales declined 7.3% to $145.7 million, and organic sales declined 6.6%. Within Proprietary Products market groups, Generics sales declined 5.7% and organic sales declined 4.5%. By contrast, Asia Pacific net sales increased 42.4%, Biologics reported organic sales growth of 23.2%, and Pharma reported organic sales growth of 21.4%.
The company increased full-year 2026 net sales guidance to $3.41 billion to $3.42 billion, increased organic net sales growth guidance to 11.3% to 11.6%, and raised adjusted-diluted EPS guidance to $9.38 to $9.48. It also updated capital spending guidance downward to $215 million to $220 million. Year-to-date operating cash flow was $403.4 million versus $503.7 million in the prior-year period, while capital expenditures were $(125.0) million. Capital allocation included $231 million of third-quarter share repurchases and $(685.3) million of repurchases over the first nine months, alongside a declared fourth-quarter dividend of $0.26 per share.
Management, verbatim
I am pleased to report strong third-quarter 2026 results, with net sales and adjusted EPS exceeding our expectations. Our results were again led by our High-Value Product (HVP) Components business. The robust sales performance drove strong operating income margin expansion and EPS growth. As a result of our team's strong execution in the third quarter, we are increasing our full-year 2026 guidance.
Michel Lagarde, President and Chief Executive Officer
I want to thank our global teams for their relentless focus on execution to deliver products and services for our customers and the patients they serve. West is a critical primary containment and drug delivery partner for pharmaceutical companies, biotechs and CDMOs around the world.
Michel Lagarde, President and Chief Executive Officer
Not in the filing
stated, not guessed- Quarterly operating cash flow was not reported.
- Quarterly free cash flow was not reported.
- Free cash flow for the nine months ended September 30, 2026 was not reported.
- Quarterly cash and debt balances were not reported.
- Prior-quarter financial comparisons were not reported for the key operating metrics.
- Full-year 2026 gross margin, operating expenses, and tax-rate guidance were not reported. The release did not provide a separately supplied previous outlook section for actual-versus-prior-guidance comparisons.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
West Pharmaceutical Services (NYSE: WST) released its third-quarter 2026 earnings via an SEC Form 8‑K, highlighting revenue growth and an increase in full-year guidance.
Ticker impact
West Pharmaceutical Services reported Q3 2026 results and raised full-year net sales and adjusted EPS guidance.
likely upward pressure as investors price in higher sales and EPS expectations
The company increased full-year net sales guidance to $3.41‑$3.42B and adjusted EPS to $9.38‑$9.48, indicating robust performance.
Market effects
Positive for injectable solutions and drug delivery sector as peers may see demand lift.
U.S. healthcare and biotech investors may react favorably.
Global pharma manufacturers may benefit from West's growth outlook.
Counterpoint
If the guidance raise is already priced in, the stock could face disappointment on actual results.
Key entities
- companyWest Pharmaceutical Services
Provider of injectable solutions and services.
- executiveMichel Lagarde
President and CEO of West Pharmaceutical Services.
